221 related articles for article (PubMed ID: 32454402)
1. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
2. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma.
Kleinmanns K; Bischof K; Anandan S; Popa M; Akslen LA; Fosse V; Karlsen IT; Gjertsen BT; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102782. PubMed ID: 32454401
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond.
Kleinmanns K; Fosse V; Bjørge L; McCormack E
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260974
[TBL] [Abstract][Full Text] [Related]
4. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer.
Fung K; Sharma SK; Keinänen O; Roche KL; Lewis JS; Zeglis BM
Mol Pharm; 2020 Aug; 17(8):3140-3147. PubMed ID: 32644804
[TBL] [Abstract][Full Text] [Related]
5. Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model.
Debie P; Vanhoeij M; Poortmans N; Puttemans J; Gillis K; Devoogdt N; Lahoutte T; Hernot S
Mol Imaging Biol; 2018 Jun; 20(3):361-367. PubMed ID: 29090412
[TBL] [Abstract][Full Text] [Related]
6. Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model.
Ceppi L; Bardhan NM; Na Y; Siegel A; Rajan N; Fruscio R; Del Carmen MG; Belcher AM; Birrer MJ
ACS Nano; 2019 May; 13(5):5356-5365. PubMed ID: 31009198
[TBL] [Abstract][Full Text] [Related]
7. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
8. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.
Harlaar NJ; Koller M; de Jongh SJ; van Leeuwen BL; Hemmer PH; Kruijff S; van Ginkel RJ; Been LB; de Jong JS; Kats-Ugurlu G; Linssen MD; Jorritsma-Smit A; van Oosten M; Nagengast WB; Ntziachristos V; van Dam GM
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):283-290. PubMed ID: 28404198
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.
Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T
Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928
[TBL] [Abstract][Full Text] [Related]
10. Near-infrared dye-labeled antibody COC183B2 enables detection of tiny metastatic ovarian cancer and optimizes fluorescence-guided surgery.
Chen J; Guo Y; Li H; Zhang C; Chang X; Ma R; Cheng H; Ye X; Cui H; Li Y
J Surg Oncol; 2020 Nov; 122(6):1207-1217. PubMed ID: 32705686
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
12. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
[TBL] [Abstract][Full Text] [Related]
13. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
14. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
15. A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.
Hoogstins CE; Tummers QR; Gaarenstroom KN; de Kroon CD; Trimbos JB; Bosse T; Smit VT; Vuyk J; van de Velde CJ; Cohen AF; Low PS; Burggraaf J; Vahrmeijer AL
Clin Cancer Res; 2016 Jun; 22(12):2929-38. PubMed ID: 27306792
[TBL] [Abstract][Full Text] [Related]
16. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
17. NIR-II Fluorescence Imaging for the Detection and Resection of Cancerous Foci and Lymph Nodes in Early-Stage Orthotopic and Advanced-Stage Metastatic Ovarian Cancer Models.
Pu T; Liu Y; Pei Y; Peng J; Wang Z; Du M; Liu Q; Zhong F; Zhang M; Li F; Xu C; Zhang X
ACS Appl Mater Interfaces; 2023 Jul; 15(27):32226-32239. PubMed ID: 37385963
[TBL] [Abstract][Full Text] [Related]
18. Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
Morse CB; Voillet V; Bates BM; Chiu EY; Garcia NM; Gottardo R; Greenberg PD; Anderson KG
Gynecol Oncol; 2021 Feb; 160(2):427-437. PubMed ID: 33229044
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.
De Thaye E; Van de Vijver K; Van der Meulen J; Taminau J; Wagemans G; Denys H; Van Dorpe J; Berx G; Ceelen W; Van Bocxlaer J; De Wever O
Sci Rep; 2020 Apr; 10(1):6688. PubMed ID: 32317693
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
